NorthWest Biotherapeutics Inc (NWBO)

[flipper44]

That was Pyrr's position. Go figure.

I disagree. It has been all about safety with GBM and original DCVax-L. Inflammation can occur with either tumor progression or pseudo-progression from chemoradiation therapeutic response, and they could not afford to risk further swelling from a stronger therapy like Direct (that can cause temporary swelling from things like fluid buildup and t-cell infiltration) when they are trying to establish a safe baseline therapy for a new technology. Pyrr would agree with you to a T however.

OK. My filter will be enabled again.

Just a note on the issue of inflammation of the cranial cavity, since the tumor is resectioned it would seem that such swelling would not be dramatic regardless of the responsiveness of the L product. -- Schnauzer